Form EFFECT Cadrenal Therapeutics,
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 2, 2024 |
| Accession Number: | 0001213900-24-028970 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cadrenal expands CAD-1005 strategy after rival's Phase 3 failure
- Tennant Company Reports Second Quarter 2026 Results
- Backstreet Surveillance Launches “Beyond the Demo: The Ground Truth” — A New Podcast Cutting Through the Hype in Commercial Security and Surveillance
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
